Jasper Therapeutics Stock Current Valuation

JSPR Stock  USD 5.80  0.24  4.32%   
Valuation analysis of Jasper Therapeutics helps investors to measure Jasper Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 02/27/2025, Enterprise Value Over EBITDA is likely to drop to 0.03. In addition to that, Enterprise Value Multiple is likely to drop to 0.03. Fundamental drivers impacting Jasper Therapeutics' valuation include:
Price Book
0.9967
Enterprise Value
-7 M
Enterprise Value Ebitda
(3.42)
Overvalued
Today
5.80
5.85.85.65.5768.868.785.85.811.22100%
Please note that Jasper Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Jasper Therapeutics is based on 3 months time horizon. Increasing Jasper Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Jasper stock is determined by what a typical buyer is willing to pay for full or partial control of Jasper Therapeutics. Since Jasper Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Jasper Stock. However, Jasper Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  5.8 Real  5.57 Target  68.78 Hype  5.8 Naive  1.22
The intrinsic value of Jasper Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Jasper Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
5.57
Real Value
15.19
Upside
Estimating the potential upside or downside of Jasper Therapeutics helps investors to forecast how Jasper stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Jasper Therapeutics more accurately as focusing exclusively on Jasper Therapeutics' fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
-1.28-1.13-1.01
Details
Hype
Prediction
LowEstimatedHigh
0.295.8015.42
Details
Naive
Forecast
LowNext ValueHigh
0.021.2210.84
Details
11 Analysts
Consensus
LowTarget PriceHigh
62.5968.7876.34
Details

Jasper Therapeutics Company Current Valuation Analysis

Jasper Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Jasper Therapeutics Current Valuation

    
  (7.03 M)  
Most of Jasper Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jasper Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Jasper Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for Jasper Therapeutics is extremely important. It helps to project a fair market value of Jasper Stock properly, considering its historical fundamentals such as Current Valuation. Since Jasper Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jasper Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jasper Therapeutics' interrelated accounts and indicators.
0.85-0.84-0.94-0.860.99-0.430.930.280.621.0-0.75-0.43-0.84-0.430.930.341.00.92-0.43-0.1
0.85-0.71-0.92-0.790.78-0.660.77-0.10.670.86-0.52-0.66-0.77-0.660.890.190.860.82-0.66-0.1
-0.84-0.710.770.96-0.870.45-0.95-0.38-0.58-0.820.860.450.720.45-0.9-0.4-0.84-0.830.45-0.33
-0.94-0.920.770.86-0.920.58-0.84-0.25-0.59-0.940.730.580.820.58-0.95-0.26-0.96-0.910.580.17
-0.86-0.790.960.86-0.890.61-0.9-0.39-0.65-0.850.890.610.830.61-0.95-0.23-0.87-0.830.61-0.13
0.990.78-0.87-0.92-0.89-0.440.920.430.620.98-0.84-0.44-0.84-0.440.930.320.990.91-0.44-0.1
-0.43-0.660.450.580.61-0.44-0.37-0.17-0.85-0.430.551.00.551.0-0.650.17-0.48-0.481.00.18
0.930.77-0.95-0.84-0.90.92-0.370.330.530.91-0.79-0.37-0.68-0.370.930.560.920.94-0.370.28
0.28-0.1-0.38-0.25-0.390.43-0.170.330.160.25-0.76-0.17-0.2-0.170.330.20.320.35-0.170.01
0.620.67-0.58-0.59-0.650.62-0.850.530.160.62-0.58-0.85-0.72-0.850.67-0.170.630.54-0.85-0.24
1.00.86-0.82-0.94-0.850.98-0.430.910.250.62-0.72-0.43-0.85-0.430.920.310.990.91-0.43-0.14
-0.75-0.520.860.730.89-0.840.55-0.79-0.76-0.58-0.720.550.680.55-0.83-0.26-0.78-0.760.55-0.08
-0.43-0.660.450.580.61-0.441.0-0.37-0.17-0.85-0.430.550.551.0-0.650.17-0.48-0.481.00.18
-0.84-0.770.720.820.83-0.840.55-0.68-0.2-0.72-0.850.680.550.55-0.780.21-0.83-0.610.550.39
-0.43-0.660.450.580.61-0.441.0-0.37-0.17-0.85-0.430.551.00.55-0.650.17-0.48-0.481.00.18
0.930.89-0.9-0.95-0.950.93-0.650.930.330.670.92-0.83-0.65-0.78-0.650.360.950.95-0.650.06
0.340.19-0.4-0.26-0.230.320.170.560.2-0.170.31-0.260.170.210.170.360.340.60.170.69
1.00.86-0.84-0.96-0.870.99-0.480.920.320.630.99-0.78-0.48-0.83-0.480.950.340.94-0.48-0.11
0.920.82-0.83-0.91-0.830.91-0.480.940.350.540.91-0.76-0.48-0.61-0.480.950.60.94-0.480.15
-0.43-0.660.450.580.61-0.441.0-0.37-0.17-0.85-0.430.551.00.551.0-0.650.17-0.48-0.480.18
-0.1-0.1-0.330.17-0.13-0.10.180.280.01-0.24-0.14-0.080.180.390.180.060.69-0.110.150.18
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Jasper Therapeutics has a Current Valuation of (7.03 Million). This is 100.05% lower than that of the Biotechnology sector and 100.15% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.04% higher than that of the company.

Jasper Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jasper Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jasper Therapeutics could also be used in its relative valuation, which is a method of valuing Jasper Therapeutics by comparing valuation metrics of similar companies.
Jasper Therapeutics is currently under evaluation in current valuation category among its peers.

Jasper Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jasper Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jasper Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

Jasper Fundamentals

Return On Equity-0.71
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-400%-200%0%200%
Return On Asset-0.41
Current Valuation(7.03 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-350%-300%-250%-200%-150%-100%-50%
Shares Outstanding15 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%
Shares Owned By Insiders1.27 %
Shares Owned By Institutions98.73 %
Number Of Shares Shorted2.72 M
Price To Book1.00 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-250%-200%-150%-100%-50%
EBITDA(64.98 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%
Net Income(64.47 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%1,200%
Cash And Equivalents60.81 M
Cash Per Share1.60 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%0%
Total Debt2.79 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3120%40%60%80%100%120%
Debt To Equity0.07 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-300%-250%-200%-150%-100%-50%
Current Ratio9.56 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-60%-50%-40%-30%-20%-10%
Book Value Per Share5.58 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-140%-120%-100%-80%-60%-40%-20%
Cash Flow From Operations(52.07 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%
Short Ratio2.77 X
Earnings Per Share(4.95) X
Target Price59.1
Number Of Employees45
Beta2.12
Market Capitalization87.01 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Total Asset94.89 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%50%100%150%200%250%300%
Retained Earnings(169.6 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%3,000%
Working Capital76.56 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Net Asset94.89 M

About Jasper Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Jasper Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jasper Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jasper Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Jasper Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Jasper Stock

  0.78OPT OptheaPairCorr
  0.76LTRN Lantern PharmaPairCorr
  0.75GANX Gain TherapeuticsPairCorr
  0.74PHGE Biomx IncPairCorr
  0.69CUE Cue BiopharmaPairCorr
The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.
The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.